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Abstract 
Recently, metastatic renal cell carcinoma (mRCC) treatment has changed dramatically with 
the onset of new therapies against molecular targets replacing immunotherapy as standard 
treatment. We report the case of a 49-year-old patient with a moderately differentiated 
renal clear cell carcinoma without extracapsular extension who underwent radical 
nephrectomy. Eight months after surgery, he developed a thyroid metastasis which was also 
treated surgically with a hemithyroidectomy. Seventy-five months after nephrectomy, the 
patient presented an upper gastrointestinal bleeding due to a duodenal metastasis that 
infiltrates the head of the pancreas. The treatment applied was surgery by 
duodenopancreatectomy, with positive surgical margins in the pathologic study. In addition 
to this, the extension study showed lung metastases requiring initiation of systemic 
treatment with sunitinib. The patient presented an excellent response to treatment, 
showing complete clinical and radiological response at 5 months of treatment (RECIST 
criteria) and a disease-free survival of 48 months until now, without evidence of toxicity. RCC 
has the potential to metastasize to almost any location, but thyroid and duodenal 
metastases in RCC are extremely rare. Moreover, this case also highlights the good 
responses that can be achieved in terms of disease-free survival, low toxicity and quality of 
life in this new era of therapies against molecular targets. 
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Introduction 
Renal cell carcinoma (RCC) represents approximately 85% of all renal tumors [1]. 
Initial treatment for localized disease is surgical, but between 20 and 30% of patients 
relapse with a mean time to progression of 1–2 years. Approximately one third of 
patients present with metastatic disease with an overall survival of 12–15 months [2]. 
Few years ago, metastatic RCC (mRCC) patients had few treatment options. 
Cytokines like interleukin-2 (IL-2) and interferon-α (IFN-α) were the standard 
treatment, but were associated with low response rates and significant toxicity. 
In the last 5 years, mRCC treatment has changed dramatically, with the onset of new 
therapies against molecular targets such as the vascular-endothelial growth factor 
receptor (VEGFR) and mTOR signalling pathway. Both treatments in both first and 
second line have shown clear benefits in these patients and have replaced 
immunotherapy as standard treatment [3, 4]. 
Case Report 
A 49-year-old male with a personal history of arterial hypertension and smoking was referred to 
the urology department due to a history of monosymptomatic macroscopic hematuria. The initial 
ultrasonography study demonstrated an 8.5-cm solid mass with a central necrotic area at the lower 
pole of the left kidney, compatible with RCC. The computed tomography (CT) scan confirmed the 
presence of a renal tumor that invades the renal sinus, but without vascular or regional node 
compromise or distant metastases. Radical nephrectomy was then performed with the pathological 
diagnosis of a moderately differentiated renal clear cell carcinoma with absence of extracapsular or 
vascular extension (T2aN0M0). 
Without postoperative complications, the patient continued routine follow-up visits every 3 
months in the urology service. Eight months after nephrectomy, while the patient was asymptomatic, 
a control CT demonstrated a 4-cm thyroid nodule in the left lobe without any other finding. The 
patient was then referred to endocrinology where the study was completed with a thyroid 
scintigraphy that confirmed the cold thyroid nodule diagnosis. Thyroid function tests were normal 
and fine needle aspiration cytology was performed, with the pathological result compatible with 
follicular proliferation. Nevertheless, left hemithyroidectomy was carried out with the pathological 
result of renal clear cell carcinoma metastases associated with a thyroid nodular hyperplasia. The CT 
performed after surgical intervention revealed no other compromised organs or metastatic extension. 
Subsequently, the patient was referred to our medical oncology service where routine follow-up 
visits were carried out keeping an expectant attitude since the CT scan, physical examination and lab 
tests performed routinely were normal. 
Seventy-five months after nephrectomy (67 months after the first metastases), the patient 
presented at the emergency department with a history of one episode of melena that required his 
admission to the gastroenterology service where the endoscopic study revealed an upper 
gastrointestinal bleeding due to a duodenal ulcer (not biopsied) that required sclerotherapy 
treatment. Helicobacter pylori (Hp) test was positive and the patient received eradication treatment 
with subsequent negativization of breath test. 
However, 5 months after the first episode of duodenal bleeding, the patient was admitted again to 
the gastroenterology service due to another upper gastrointestinal bleeding episode, this time 
associated with fatigue. The lab test was significant for microcytic hypochromic anemia with 
hemoglobin of 5.3 g/dl, requiring transfusion of 3 erythrocyte concentrates and bowel rest. The 
gastroscopy again revealed a duodenal ulcer (biopsy was taken at that time) corresponding to the 
same lesion detected 5 months earlier without signs of healing despite sclerotherapy and Hp 
eradication treatment. Because of this and the big size of ulcer, an abdominal CT scan was performed  
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showing the presence of enlargement of the head of the pancreas without any other finding. The study 
was completed with an ultrasound endoscopy that confirmed the presence of a 4-cm solid mass in the 
head of the pancreas with ‘neoplastic aspect’ that infiltrated the adjacent duodenal wall. The 
pathologic result confirmed the presence of metastatic infiltration of renal clear cell carcinoma in 
duodenal mucosa. For that reason, it was decided to carry out a duodenopancreatectomy in which the 
pathological study showed the presence of multiple metastatic invasion of renal clear cell carcinoma 
in pancreas and duodenal wall with positive surgical margins. After recovery from a postoperative 
period complicated with diabetes mellitus and steatorrhea, a new control CT scan was performed in 
April 2007 (82 months after nephrectomy) showing the presence of a 1.4-cm left lung nodule 
compatible with metastases (fig. 1). 
Given the presence of lung metastases and positive surgical margins in duodenopancreatectomy, it 
was decided to start first-line systemic treatment with sunitinib (50 mg once a day for 4 weeks with 2 
weeks rest) in May 2007. After 5 months of treatment, the patient showed complete response with 
disappearance of lung metastases in the control CT scan as well as absence of metastatic disease in 
other organs without toxicity (fig. 1). 
Currently, after 48 months of follow-up (132 months after nephrectomy), the patient continues 
treatment with sunitinib at the same dose, maintaining complete response in regular control CT 
studies (RECIST criteria), with good tolerance to treatment except for an episode of fever and 
moderate asthenia that has not required treatment adjustment, and maintaining an excellent 
performance status (ECOG 0) at all times. 
Discussion 
RCC has the potential to metastasize to almost any location, the most common sites 
being lung, lymph nodes, liver, bone, adrenal glands and brain. 
Thyroid metastases in RCC are extremely rare, representing less than 5% of cases, 
most of which are metachronous, with a mean latency period of about 10 years. The 
usual clinical presentation is of a thyroid nodule or goiter with normal thyroid function 
tests, which in the scintigraphy behaves like cold nodules. Our patient presented with 
left thyroid lobe metastases 8 months after nephrectomy that required 
hemithyroidectomy as treatment. The clinical presentation was similar to data 
reported in the literature, emphasizing the importance of raised suspicion of 
metastases in all patients with a history of RCC and thyroid volume increase [5]. 
Likewise, only 28 cases of duodenal metastases from RCC have been described, thus 
turning it into a rare entity. The vast majority of cases described presented upper 
gastrointestinal bleeding, but may also show anemia, fatigue, bowel obstruction or 
jaundice. The mean time of presentation after nephrectomy is approximately 7.9 ± 4.7 
years, and the most common form of treatment is surgical resection by 
duodenopancreatectomy, besides other therapeutic options such as embolization, 
palliative radiotherapy or palliative gastrojejunostomy [6]. Our patient presented with 
duodenal metastases that compromised the head of the pancreas, and presenting with 
upper gastrointestinal bleeding. The treatment applied in this case was surgery by 
duodenopancreatectomy, with the inconvenience that the pathology result detected 
positive surgical margins and also that the extension study showed lung metastases 
requiring initiation of systemic treatment. 
Sunitinib is a multitargeted tyrosine kinase inhibitor that predominantly targets 
VEGF activity. It was approved by the FDA (Food and Drug Administration) and EMA 
(European Medicines Agency) for the treatment of mRCC since 2007, thanks to the  
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results obtained in a randomized, double-blind, multicenter phase III study that 
compared single-agent sunitinib versus IFN-α in first-line treatment. This study 
demonstrates the superiority of sunitinib vs. IFN-α, with a mean disease-free survival 
of 11 vs. 5 months, a response rate of 31 vs. 6%, and an overall survival of 28 vs. 14 
months [3, 7]. Our patient presented an excellent response to sunitinib treatment, 
showing complete clinical and radiological response at 5 months of treatment (RECIST 
criteria) and a disease-free survival of 48 months until now, without evidence of 
toxicity, and with an excellent performance status that allows him to work and develop 
his life normally. 
This case report highlights the importance of close follow-up and the raised 
suspicion level that we must keep in nephrectomized RCC patients at the onset of new 
symptoms. Moreover, this case also highlights the good responses that can be achieved 
in terms of disease-free survival, low toxicity and quality of life in this new era of 
therapies against molecular targets; even, as in our case, better results than those 
described in the literature. 
 
 
Fig. 1. Computed tomography scan of the chest showing a metastatic nodule in left lung before 
systemic treatment with Sunitinib (a), and complete response after 5 months of treatment (b). 
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